Redsense Medical AB sees continued order intake in Europe despite the corona crisis
The COVID-19 pandemic has prompted governments all over Europe to implement far-reaching restrictions and lockdowns in an effort to curb the outbreak and mitigate its toll on society. As the various sanctions now cautiously and gradually are being relaxed and lifted across different countries and the wheels of the economy slowly are put in motion, Redsense Medical notes that the strict lockdowns as yet have not had any material impact on the Company’s order intake in Europe.
Throughout the crisis, the Company has continued to receive orders on the European markets of operation like Netherlands, France, Germany and the UK. This is in line with the previously disclosed assessment that Redsense’s products should show relative demand resilience to the COVID-19 pandemic since they address a need for regular and life-supporting treatments.
”We are pleased to conclude that orders have been coming in steadily on the European markets, the uncertain times notwithstanding; neither the crisis nor the European lockdown regimes have impacted demand for our solutions severely, and we have been able to continue with our operations and efforts to contribute to better and safer care,”says Patrik Byhmer, CEO of Redsense Medical AB.
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.